MCID: MLG154
MIFTS: 25

Malignant Sertoli-Leydig Cell Tumor of the Ovary

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Malignant Sertoli-Leydig Cell Tumor of the Ovary

MalaCards integrated aliases for Malignant Sertoli-Leydig Cell Tumor of the Ovary:

Name: Malignant Sertoli-Leydig Cell Tumor of the Ovary 58
Virilizing Ovarian Tumor 58 70
Ovarian Malignant Sertoli-Leydig Cell Tumor 58
Ovarian Sertoli-Leydig Cell Cancer 58
Sertoli-Leydig Cell Tumor of Ovary 70
Sertoli-Leydig Cell Tumor 70
Arrhenoblastoma 58
Androblastoma 58

Characteristics:

Orphanet epidemiological data:

58
malignant sertoli-leydig cell tumor of the ovary
Age of onset: Adult,Elderly; Age of death: adult,elderly;

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

ICD10 via Orphanet 33 C56
UMLS via Orphanet 71 C0003810 C0036769 C0206723
Orphanet 58 ORPHA99916
UMLS 70 C0003810 C0206723 C0342515

Summaries for Malignant Sertoli-Leydig Cell Tumor of the Ovary

MalaCards based summary : Malignant Sertoli-Leydig Cell Tumor of the Ovary, also known as virilizing ovarian tumor, is related to virilizing ovarian tumor and sertoli-leydig cell tumor, and has symptoms including hoarseness An important gene associated with Malignant Sertoli-Leydig Cell Tumor of the Ovary is DICER1 (Dicer 1, Ribonuclease III). The drugs Bevacizumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and pituitary.

Related Diseases for Malignant Sertoli-Leydig Cell Tumor of the Ovary

Graphical network of the top 20 diseases related to Malignant Sertoli-Leydig Cell Tumor of the Ovary:



Diseases related to Malignant Sertoli-Leydig Cell Tumor of the Ovary

Symptoms & Phenotypes for Malignant Sertoli-Leydig Cell Tumor of the Ovary

UMLS symptoms related to Malignant Sertoli-Leydig Cell Tumor of the Ovary:


hoarseness

Drugs & Therapeutics for Malignant Sertoli-Leydig Cell Tumor of the Ovary

Drugs for Malignant Sertoli-Leydig Cell Tumor of the Ovary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2 216974-75-3
2
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
3
Etoposide Approved Phase 2 33419-42-0 36462
4
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
5
Bleomycin Approved, Investigational Phase 2 11056-06-7 5360373
6
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
7 Angiogenesis Inhibitors Phase 2
8 Immunoglobulin G Phase 2
9 Immunoglobulins, Intravenous Phase 2
10 Antineoplastic Agents, Immunological Phase 2
11 Antibodies Phase 2
12 Mitogens Phase 2
13 Immunoglobulins Phase 2
14 Immunologic Factors Phase 2
15 Antibodies, Monoclonal Phase 2
16 Endothelial Growth Factors Phase 2
17 Tubulin Modulators Phase 2
18 Antimitotic Agents Phase 2
19 Albumin-Bound Paclitaxel Phase 2
20 Antibiotics, Antitubercular Phase 2
21 Etoposide phosphate Phase 2
22 Anti-Bacterial Agents Phase 2
23
Vincristine Approved, Investigational 2068-78-2, 57-22-7 5978
24
Dactinomycin Approved, Investigational 50-76-0 2019 457193
25
Ifosfamide Approved 3778-73-2 3690
26
Doxorubicin Approved, Investigational 23214-92-8 31703
27
Cyclophosphamide Approved, Investigational 50-18-0, 6055-19-2 2907
28
Liposomal doxorubicin 31703
29
Isophosphamide mustard 100427

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy Completed NCT00006227 Phase 2 Paclitaxel
2 A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary Completed NCT00748657 Phase 2
3 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary Active, not recruiting NCT01042522 Phase 2 Carboplatin;Cisplatin;Etoposide Phosphate;Paclitaxel
4 DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study Recruiting NCT01247597
5 International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158
6 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Active, not recruiting NCT00565903

Search NIH Clinical Center for Malignant Sertoli-Leydig Cell Tumor of the Ovary

Genetic Tests for Malignant Sertoli-Leydig Cell Tumor of the Ovary

Anatomical Context for Malignant Sertoli-Leydig Cell Tumor of the Ovary

MalaCards organs/tissues related to Malignant Sertoli-Leydig Cell Tumor of the Ovary:

40
Ovary, Endothelial, Pituitary

Publications for Malignant Sertoli-Leydig Cell Tumor of the Ovary

Articles related to Malignant Sertoli-Leydig Cell Tumor of the Ovary:

(show all 22)
# Title Authors PMID Year
1
Adolescent ovarian thecoma presenting as progressive hyperandrogenism: case report and review of the literature. 61
32174224 2020
2
[Virilizing ovarian tumor: the challenges of differential diagnosis]. 61
32202730 2019
3
Persistent Poor Metabolic Profile in Postmenopausal Women With Ovarian Hyperandrogenism After Testosterone Level Normalization. 61
31073547 2019
4
Steroid cell tumor: A rare virilizing ovarian tumor. 61
26458674 2015
5
[Virilizing ovarian tumor: a rare cause of androgenetic alopecia]. 61
25813185 2015
6
Virilizing ovarian tumor in a 14-year-old female with a prior familial multinodular goiter. 61
18570301 2008
7
Ovarian thecoma with androgenic manifestations in a postmenopausal woman. 61
16864153 2006
8
HPLC-RIA analysis of steroid hormone profile in a virilizing stromal tumor of the ovary. 61
15560921 2004
9
Intraoperative testosterone assay for virilizing ovarian tumor topographic assessment: report of a Leydig cell tumor of the ovary in a premenopausal woman with an adrenal incidentaloma. 61
12107203 2002
10
Virilizing ovarian tumor of cell tumor type not otherwise specified: a case report. 61
9859028 1998
11
Virilizing ovarian tumor of low malignant potential associated with antecedent tamoxifen use for breast cancer. 61
9570983 1998
12
Secretion of prorenin by a virilizing ovarian tumor. 61
1318255 1992
13
[Virilizing ovarian tumor in an adolescent]. 61
2158055 1990
14
The effects of continuous androgen secretion on the hypothalamic-pituitary axis in woman: evidence from a luteinized thecoma of the ovary. 61
6086692 1984
15
Steroid hormones in ovarian vein and cyst fluid of a virilizing stromal tumor. 61
214729 1978
16
The steroid profile of a virilizing ovarian tumor. 61
150557 1978
17
Virilizing ovarian tumor in a 2 1/2-year-old girl. 61
4290148 1967
18
[MORPHOLOGICAL AND HISTOCHEMICAL FINDINGS IN A CASE OF VIRILIZING OVARIAN TUMOR]. 61
14118565 1963
19
[Schizophrenia-like psychoses in virilizing ovarian tumor]. 61
13229344 1954
20
[Chemical and crystalline demonstration of androgens and corticoids in urine and tumor tissue in cases of virilizing ovarian tumor]. 61
14951459 1952
21
[Clinical case of virilizing ovarian tumor of arrhenoma type]. 61
14873088 1951
22
A new case of virilizing ovarian tumor. 61
18917833 1947

Variations for Malignant Sertoli-Leydig Cell Tumor of the Ovary

Expression for Malignant Sertoli-Leydig Cell Tumor of the Ovary

Search GEO for disease gene expression data for Malignant Sertoli-Leydig Cell Tumor of the Ovary.

Pathways for Malignant Sertoli-Leydig Cell Tumor of the Ovary

GO Terms for Malignant Sertoli-Leydig Cell Tumor of the Ovary

Sources for Malignant Sertoli-Leydig Cell Tumor of the Ovary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....